Hepatitis C: A Modern Market Access Perspective
An in-depth look at current trends in the Hepatitis C market landscape. Our presenters look at reimbursement decisions made by the Scottish Medicines Consortium (SMC)—the first agency to review all the new Hepatitis C treatments—to see what drugs are moving to market and where others have stumbled.
This webinar provides a data-driven analysis of SMC reimbursement decisions for Hepatitis C drugs including:
- Impact of decisions, time to reimbursement decisions, indication, and clinical rationale
- Role of restrictions in the reimbursement process
- Potential impact of Brexit on SMC reimbursement decisions in connection with the European Medicines Association’s (EMA) regulatory decisions